NR3C2 and muscular dystrophy: Prophylactic MR antagonist treatment for repeated, intense exercise may stabilize damaged myofibers and reduce immune cell and fibroblast infiltration into damaged muscle in a similar manner as muscular dystrophy patients without compromising the normal immune response to pathogens (Rafael-Fortney et al., 2011; Lowe et al., 2016; Bryant et al., 2017; Chadwick et al., 2017a; Hauck et al., 2019).